In the race to supply vaccines to end the COVID-19 pandemic, U.S. drug developer Novavax turned to emerging Europe to speed up production with a pair of deals that endorsed a growing trend for consolidation in the region.
FOCUS-Big pharma and private equity seek healthy returns in Europe’s east
2021-05-20T06:03:35-04:00May 20th, 2021|